Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzastaurin for the Prevention of Arterial Events in vEDS
NCT05463679Phase 3Suspended
- Sponsor
- Aytu BioPharma
- Start
- Jan 2025
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of enzastaurin in Vascular Ehlers-Danlos syndrome (VEDS), sponsored by Aytu BioPharma. Started Jan 2025; status: suspended.
02
Drugs
enzastaurin
03
Conditions
Vascular Ehlers-Danlos syndrome (VEDS)
Beyond the preview
Go deeper on NCT05463679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05463679.